BioLingus, a biotechnology company based in Switzerland, is at the forefront of pioneering oral (sublingual) delivery of peptides and proteins for the treatment of chronic diseases and immuno-therapy using our innovative formulation technology. Our primary focus is on developing products for addressing metabolic diseases and various immuno-therapies. Specifically for diabetes, our primary compounds consist of an oral biobetter of liraglutide and exenatide (GLP-1) for type II diabetes. Additionally, we are working on a combination product of insulin and GLP1, and exploring the potential use of low dose IL-2 for early onset juvenile type I diabetes.